Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MF59-adjuvanted H5N1 vaccine + enhanced trivalent influenza vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MF59-eH5N1 + eTIV is a combination of two influenza vaccines administered together. The first component is an H5N1 (avian influenza) vaccine adjuvanted with MF59, an oil-in-water emulsion adjuvant that enhances both antibody and T-cell responses to the antigen. The second component is an enhanced trivalent inactivated seasonal influenza vaccine (eTIV). The combination aims to provide protection against both pandemic (H5N1) and seasonal strains of influenza. MF59 allows for dose sparing and broader cross-reactivity against viral strains not included in the vaccine formulation. Clinical studies have shown that this approach increases immunogenicity across age groups without significant safety concerns[2][3][5]. Novartis Vaccines developed the original formulations; CSL Seqirus now manufactures related products.
- Other names
- MF59-adjuvanted H5N1 vaccineMF-59-adjuvanted H5N1 vaccineMF 59-adjuvanted H5N1 vaccineenhanced trivalent influenza vaccineMF59-eH5N1 + eTIV
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on MF59-adjuvanted H5N1 vaccine + enhanced trivalent influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MF59-adjuvanted H5N1 vaccine + enhanced trivalent influenza vaccine.